Rafferty Asset Management
RPRX icon

Rafferty Asset Management’s Royalty Pharma RPRX Stock Holding History

Rafferty Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
+3,643
New +$190K ﹤0.01% 1100
2026
Q1 		– Sell
-6,112
Closed -$236K – 1135
2025
Q4 		$236K Buy
6,112
+135
+2% +$5.15K ﹤0.01% 1051
2025
Q3 		$211K Sell
5,977
-1,003
-14% -$36.3K ﹤0.01% 1065
2025
Q2 		$251K Sell
6,980
-2,943
-30% -$97.5K ﹤0.01% 1010
2025
Q1 		$309K Sell
9,923
-4,156
-30% -$132K ﹤0.01% 956
2024
Q4 		$359K Sell
14,079
-1,748
-11% -$46.4K ﹤0.01% 987
2024
Q3 		$448K Buy
15,827
+847
+6% +$23.5K ﹤0.01% 960
2024
Q2 		$395K Sell
14,980
-1,722
-10% -$47.7K ﹤0.01% 1012
2024
Q1 		$507K Buy
16,702
+2,365
+16% +$69.7K ﹤0.01% 975
2023
Q4 		$403K Buy
14,337
+1,737
+14% +$47.7K ﹤0.01% 1012
2023
Q3 		$342K Buy
12,600
+2,841
+29% +$84.4K ﹤0.01% 1002
2023
Q2 		$300K Buy
9,759
+1,798
+23% +$60.9K ﹤0.01% 1040
2023
Q1 		$287K Buy
7,961
+866
+12% +$32.1K ﹤0.01% 1048
2022
Q4 		$280K Buy
7,095
+1,468
+26% +$61.3K ﹤0.01% 1032
2022
Q3 		$226K Sell
5,627
-229
-4% -$9.78K ﹤0.01% 1069
2022
Q2 		$246K Sell
5,856
-5,553
-49% -$228K ﹤0.01% 993
2022
Q1 		$444K Sell
11,409
-11,524
-50% -$453K ﹤0.01% 1037
2021
Q4 		$914K Buy
22,933
+3,016
+15% +$117K ﹤0.01% 917
2021
Q3 		$720K Buy
19,917
+8,704
+78% +$338K ﹤0.01% 958
2021
Q2 		$460K Buy
11,213
+3,060
+38% +$130K ﹤0.01% 1088
2021
Q1 		$356K Sell
8,153
-3,249
-28% -$154K ﹤0.01% 1042
2020
Q4 		$571K Buy
11,402
+1,579
+16% +$67K 0.01% 653
2020
Q3 		$413K Buy
+9,823
New +$421K 0.01% 739

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's RPRX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 3,643 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #1100 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in RPRX as recently as Q4 2025.

Rafferty Asset Management first reported a position in RPRX in Q3 2020 and has held it in 23 quarters since. The position peaked at $914K in Q4 2021. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Rafferty Asset Management held 3,643 shares of Royalty Pharma worth $204K as of Q2 2026.
  • Royalty Pharma was a new Rafferty Asset Management position in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1100 holding.
  • Rafferty Asset Management first reported a position in Royalty Pharma in Q3 2020 and has held it in 23 quarters since.
  • Rafferty Asset Management's Royalty Pharma position peaked at $914K in Q4 2021.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.